国金证券：产业、业绩与资金三维共振把握创新药底部布局机遇

中金财经07-15

智通财经APP获悉，国金证券称，港股创新药前期受海外流动性压制持续回调，估值回落至阶段低位，资金层面呈现结构性切换：外资减持接近底部，南下资金持仓占比提升，板块定价逻辑逐步转向国内基本面驱动+出海预期弹性；同时美股Biotech指数受并购、FDA(美国药监局)政策利好走强，全球医药情绪回暖。近期港股创新药板块交易活跃度底部回升，A/H 估值价差存在修复空间，具备管线与商业化壁垒的优质标的迎来配置...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651748763?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 07:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651748763","market":"fut","top_or_hot":-1,"title":"国金证券：产业、业绩与资金三维共振 把握创新药底部布局机遇","media":"中金财经","content":"<div>\n<p>智通财经APP获悉，国金证券称，港股创新药前期受海外流动性压制持续回调，估值回落至阶段低位，资金层面呈现结构性切换：外资减持接近底部，南下资金持仓占比提升，板块定价逻辑逐步转向国内基本面驱动+出海预期弹性；同时美股Biotech指数受并购、FDA(美国药监局)政策利好走强，全球医药情绪回暖。近期港股创新药板块交易活跃度底部回升，A/H 估值价差存在修复空间，具备管线与商业化壁垒的优质标的迎来配置...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushizhibo/20260715/32307575.shtml\">网页链接</a>\n\n</div>\n","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国金证券：产业、业绩与资金三维共振 把握创新药底部布局机遇</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国金证券：产业、业绩与资金三维共振 把握创新药底部布局机遇\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 07:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushizhibo/20260715/32307575.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国金证券称，港股创新药前期受海外流动性压制持续回调，估值回落至阶段低位，资金层面呈现结构性切换：外资减持接近底部，南下资金持仓占比提升，板块定价逻辑逐步转向国内基本面驱动+出海预期弹性；同时美股Biotech指数受并购、FDA(美国药监局)政策利好走强，全球医药情绪回暖。近期港股创新药板块交易活跃度底部回升，A/H 估值价差存在修复空间，具备管线与商业化壁垒的优质标的迎来配置...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushizhibo/20260715/32307575.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06978","symbol_name":"永泰生物-B","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260715/32307575.shtml","article_id":"2651748763","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651748763","pubTimestamp":1784073555,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"智通财经APP获悉，国金证券称，港股创新药前期受海外流动性压制持续回调，估值回落至阶段低位，资金层面呈现结构性切换：外资减持接近底部，南下资金持仓占比提升，板块定价逻辑逐步转向国内基本面驱动+出海预期弹性；同时美股Biotech指数受并购、FDA政策利好走强，全球医药情绪回暖。近期港股创新药板块交易活跃度底部回升，A/H估值价差存在修复空间，具备管线与商业化壁垒的优质标的迎来配置机遇。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","600109":"国金证券","06978":"永泰生物-B","BK0028":"国家队","BK0276":"资本市场","BK0201":"可转债","BK0183":"MSCI概念","BK0188":"融资融券","BK1161":"生物科技","BK0012":"证金概念","BK1574":"生物医药B类股","IBBQ":"Invesco Nasdaq Biotechnology ETF","MEDX":"HORIZON KINETICS MEDICAL ETF"},"translate_title":"Guojin Securities: Three-dimensional resonance of industry, performance and capital to grasp the opportunity of the bottom layout of innovative drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"600109":1.5,"MEDX":1.5,"06978":1.5,"IBBQ":1.5},"content_text":"智通财经APP获悉，国金证券称，港股创新药前期受海外流动性压制持续回调，估值回落至阶段低位，资金层面呈现结构性切换：外资减持接近底部，南下资金持仓占比提升，板块定价逻辑逐步转向国内基本面驱动+出海预期弹性；同时美股Biotech指数受并购、FDA(美国药监局)政策利好走强，全球医药情绪回暖。近期港股创新药板块交易活跃度底部回升，A/H 估值价差存在修复空间，具备管线与商业化壁垒的优质标的迎来配置机遇。\n\r\n　　产业端，创新药出海BD(商务合作)景气上行，当前估值错配带来布局机遇。\n\r\n　　国内创新药历经投融资沉淀、技术迭代，在ADC(抗体偶联药物)、双抗、小核酸等前沿子赛道的管线储备全球领先，叠加中国创新药产业在监管审评、临床效率、开发成本三重优势拥有较高壁垒，使得中国创新药企深度嵌入全球医药产业链：全球临床试验中国内布局权重持续且快速抬升；且本土药企与MNC(跨国药企)绑定后持续深化合作具有惯性动能。但当下市场对BD估值缺位，而国金证券认为管线出海将支撑药企产业长期迭代：中短期，BD合作收益落地，显著优化国内创新药企财务基本面；中长期，驱动国内医药产业接轨全球标准，并重塑药企研发实力，倒逼国内药企开展更多中美双报临床、以及加快FIC(First-In-Class)分子研发。\n\r\n　　最后，国金证券看好出海β可持续，系众多大单品专利到期缺口持续倒逼MNC外部管线投入进入上行长周期，据统计从2023年起TOP15 MNC每年投入2000亿左右资本开支进行外部合作，截至26年7月10日，今年以来TOP15 MNC外部资本开支已达2003亿美元，接近2025全年总额的73.5%，全球医药产业并购高景气格局已基本确立。且生物医药资本支出具有可持续性：成熟的商业模式可以提供现金流保持资本支出需求端增长；同时全球生物医药技术持续迭代为资本支出提供多元化的供给。2027年起众多已达成BD的分子将在海外开启商业化周期。\n\r\n　　业绩端：后期管线有望集中上市+政策双向赋能，创新药行业进入业绩兑现黄金期。\n\r\n　　目前国内创新药包括临床Ⅲ期、NDA(申报上市)、或批准上市在内的后端管线数量持续扩容，叠加优先审评、附条件批准等通道加速新适应症落地，供给端支撑国内创新药市场持续放量。医保谈判常态化吸纳创新品种，持续打开创新药院内放量空间；且近期新版基药目录扩容，大幅拓宽创新药基层终端渠道。国金证券认为，国内龙头药企正形成“高研发投入—丰富管线—产品商业化—反哺研发”正向循环，创新药收入占比稳步提升，行业整体盈利弹性持续释放，迎来多年维度的业绩兑现窗口。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651748763","isCrawlerRequest":true}

国金证券：产业、业绩与资金三维共振 把握创新药底部布局机遇

精彩评论

国金证券：产业、业绩与资金三维共振把握创新药底部布局机遇